miR-342-5p/AnkG Pathway in Early AD Synaptic Dysfunction
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Collect peripheral blood, and if the patient consents, also collect cerebrospinal fluid..
- Who it may be relevant to
- Registry conditions: Alzheimer Disease, Biomarker in Early Diagnosis. Basic parameters: from 50 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effects of miR-342-5p/AnkG Pathway-Mediated Axon Initial Segment Filtering Injury on Early Synaptic Dysfunction in Alzheimer's Disease and Its Clinical Applications
Overview
Alzheimer's disease is the most common memory loss disease among the elderly. This disease affects the patient's memory, language, attention, and behavioral abilities. Current research has found that in the early stages of the disease, synaptic connections between brain nerve cells become abnormal, but the specific cause is still unclear. Investigators' previous research discovered that in the brains of diseased mice, certain special substances (the miR 342 5p/AnkG-mediated pathway) might be related to this abnormality, and these substances can be detected in both blood and cerebrospinal fluid. Therefore, investigators want to further explore the specific mechanisms of abnormal nerve cell connections, seek biomarkers for early detection of the disease, and provide new ideas for early diagnosis in the future.
Interventions
- Other Collect peripheral blood, and if the patient consents, also collect cerebrospinal fluid.
Collect peripheral blood, and if the patient consents, also collect cerebrospinal fluid.
Primary outcome measures
- Correlation between miR-342-5p/AnkG Pathway and Synaptic Proteins [Time frame: Within 12 weeks after enrollment]
Secondary outcome measures (1)
- The correlation between miR-342-5p/AnkG pathway and cognitive function and brain atrophy [Time frame: Within 12 weeks after enrollment]
Eligibility criteria
Inclusion criteria
Inclusion criteria for AD group:
- Meet the diagnostic criteria for "probable AD dementia" established by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)
- MMSE score between 0-23 points, Clinical Dementia Rating (CDR) score ≥0.5 points, Hachinski Ischemic Score <4 points
- Brain MRI showing bilateral temporal lobe and hippocampal atrophy
- Age ≥50 years
Inclusion criteria for control group:
- Healthy subjects with age matched to the AD group
- Normal cognitive function and good activities of daily living
- No dementia patients among first-degree relatives
- Negative brain MRI and neurological examination
Exclusion criteria
- Dementia or cognitive impairment caused by other diseases
- History of substance abuse
- Progressive primary aphasia
- Previous traumatic brain injury
- Patients with comorbid depression, schizophrenia, or severe diseases of the cardiovascular, hepatic, renal, or hematological systems
- Impaired consciousness and inability to cooperate
- Other conditions unsuitable for inclusion
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
China · 1 center
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine — Yiwu
Identifiers
NCT: NCT07353502 · KY-2025-070